Tolan DA, Ebrahim NAA, AlAli NS, Ahmed HA, Alharshan GA, Arafat AMA. Stem cell-derived immune cells in pediatric cancer therapy: From bench to bedside. World J Stem Cells 2026; 18(6): 118674 [DOI: 10.4252/wjsc.118674]
Corresponding Author of This Article
Noura A A Ebrahim, Assistant Professor, Department of Oncologic Pathology, National Cancer Institute, Cairo University, 1st Kasr Alainy Street, Cairo 11796, Al Qāhirah, Egypt. npathologist@gmail.com
Research Domain of This Article
Biology
Article-Type of This Article
review-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tolan DA, Ebrahim NAA, AlAli NS, Ahmed HA, Alharshan GA, Arafat AMA. Stem cell-derived immune cells in pediatric cancer therapy: From bench to bedside. World J Stem Cells 2026; 18(6): 118674 [DOI: 10.4252/wjsc.118674]
World J Stem Cells. Jun 26, 2026; 18(6): 118674 Published online Jun 26, 2026. doi: 10.4252/wjsc.118674
Stem cell-derived immune cells in pediatric cancer therapy: From bench to bedside
Dina A Tolan, Noura A A Ebrahim, Naif S AlAli, Hoda A Ahmed, Gharam A Alharshan, Aya Mohamed Adel Arafat
Dina A Tolan, Department of Chemistry, College of Science and Humanities, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia
Noura A A Ebrahim, Department of Oncologic Pathology, National Cancer Institute, Cairo University, Cairo 11796, Al Qāhirah, Egypt
Naif S AlAli, Family Medicine Academy, Eastern Health Cluster, Dammam 11942, Saudi Arabia
Hoda A Ahmed, Department of Chemistry, College of Science in Yanbu, Taibah University, Yanbu Governorate, Yanbu 46423, Saudi Arabia
Gharam A Alharshan, Physics Department, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh 11671, Saudi Arabia
Aya Mohamed Adel Arafat, Department of Clinical and Chemical Pathology, Kasr Al-Aini Faculty of Medicine, Cairo University, Cairo 11562, Egypt
Author contributions: Tolan DA, Ebrahim NAA, AlAli NS, Ahmed HA, Alharshan GA, and Arafat AMA contributed equally to the conceptualization, drafting, and critical revision of this manuscript.
AI contribution statement: We would like to clarify that we used Grammarly and QuillBot only as language-editing tools to improve grammar, clarity, readability, and stylistic consistency of the manuscript. Their use was limited to linguistic polishing and did not involve generation of the scientific content.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Corresponding author: Noura A A Ebrahim, Assistant Professor, Department of Oncologic Pathology, National Cancer Institute, Cairo University, 1st Kasr Alainy Street, Cairo 11796, Al Qāhirah, Egypt. npathologist@gmail.com
Received: January 8, 2026 Revised: January 30, 2026 Accepted: March 23, 2026 Published online: June 26, 2026 Processing time: 168 Days and 16.8 Hours
Core Tip
Core Tip: Immune cells generated from pluripotent or hematopoietic stem cell sources -particularly natural killer cells, T lymphocytes, and dendritic cells - represent a promising next-generation platform for pediatric cancer immunotherapy. These systems enable standardized, renewable production and genetic optimization, offering an allogeneic alternative to patient-specific cellular products with lower graft-vs-host disease risk. Advances in cytokine modulation and genome editing technologies, including CRISPR/Cas9, have further strengthened antitumor efficacy. This review critically consolidates current preclinical and early-phase clinical findings; addresses manufacturing, safety, and pediatric ethical considerations; and defines strategic directions for clinical translation.
